

Sleep Apnea Devices Market by Product (Therapeutic (PAP (CPAP, APAP, BPAP), Oral Appliances, Masks), Diagnostic (PSG, Home Sleep Testing, Oximeter)), Age, Gender, End User (Sleep Clinics, Hospitals, Home Care Settings) - Global Forecast to 2032

Market Report | 2025-07-18 | 505 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The sleep apnea devices market is valued at an estimated USD 6.93 billion in 2025 and is projected to reach USD 11.61 billion by 2032 at a CAGR of 7.6% during the forecast period. Sleep apnea devices have become essential components in sleep medicine, utilized across avarious settings, including sleep laboratories, clinical environments, hospitals, and home care. As patients increasingly seek non-invasive therapeutic alternatives, the market for Continuous Positive Airway Pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) machines is experiencing significant growth. Furthermore, emerging markets, particularly within the Asia Pacific region, present promising opportunities for expansion, driven by heightened awareness of sleep apnea and improved access to healthcare services.

"Therapeutic devices segment accounted for the highest growth rate in the sleep apnea devices market, by product, during the forecast period."

The market is divided into two main segments: therapeutic devices and diagnostic devices. Among these, the therapeutic devices segment is projected to experience the most significant growth during the upcoming forecast period. This segment encompasses a variety of products, including positive airway pressure (PAP) devices, which are commonly used to treat conditions such as obstructive sleep apnea (OSA). Additionally, it includes facial interfaces, also known as masks, that are essential for ensuring the effective delivery of therapy, as well as various accessories that enhance the functionality and comfort of these devices. Oral appliances designed to manage sleep-disordered breathing conditions also fall under this segment, along with other innovative therapeutic tools. The anticipated growth of the therapeutic devices segment is primarily driven by an increase in diagnosis rates for sleep-related disorders. This rise in diagnoses is largely supported by the growing adoption of home sleep tests, which provide a more accessible and convenient means for patients to undergo evaluation. As more individuals become aware of their sleep issues through these diagnostic methods, the demand for effective therapeutic solutions is expected to surge, further propelling

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the market forward.

"The home care settings segment accounted for the highest growth rate in the sleep apnea devices market, by end user, during the forecast period."

Among end users-hospitals, home care settings, sleep clinics, ambulatory care centers, primary centers, and others-the home care settings segment is projected to grow at the fastest rate. The growing trend towards home-based healthcare solutions is significantly transforming the landscape of medical diagnostics and treatment. In particular, the enhanced availability and accessibility of at-home sleep apnea testing is playing a crucial role in this shift. These innovations not only facilitate easier and more convenient testing for individuals suffering from sleep-related disorders but also lead to timely diagnoses. As a result, patients are able to receive appropriate treatment much faster than before. This trend is not only beneficial for patients but is also contributing to the overall expansion of the market by increasing awareness and encouraging more people to seek help for their sleep apnea concerns, ultimately fostering a healthier population.

"The Asia Pacific is expected to be the fastest-growing region in the sleep apnea devices market."

The global market for human identification technologies is segmented into five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the most significant growth rate throughout the forecast period. This trend can be attributed to the high volume of product launches and the regulatory approvals for innovative devices, which are enhancing market offerings and driving expansion in the area.

The break-up of the profile of primary participants in the sleep apnea devices market:

-□By Company Type: Tier 1 - 5%, Tier 2 - 55%, and Tier 3 -40%

-□By Designation: C-level - 37%, D-level - 48%, and Others - 15%

-□By Region: North America - 56%, Europe - 20%, Asia Pacific - 17%, Rest of the World - 7%

The key players in this market are ResMed (US), Koninklijke Philips N.V. (Netherlands), Fisher & Paykel Healthcare Limited (New Zealand), Inspire Medical Systems, Inc. (US), SomnoMed (Australia), Openairway (Canada), Compumedics Limited (Australia), Lowenstein Medical SE & Co. KG (Germany), Drive DeVilbiss International (US), BMC (China), BRAEBON Medical Corporation (Canada), DynaFlex (US), Panthera Dental (Canada), Myerson LLC (US), ProSomnus Sleep Technologies (US), Nidek Medical India (India), Tomed GmbH (Germany), LivaNova PLC (UK), Invacare Holdings Corporation (US), MPOWRX Health & Wellness Products Inc. (Canada), Nihon Kohden Corporation (Japan), SICAT GmbH & Co. Kg (Germany), Vivos Therapeutics, Inc. (US), Airway Management (US), and Apnea Sciences (US).

Research Coverage:

This research report categorizes the sleep apnea devices market by product [Therapeutic devices (PAP devices, facial interfaces, accessories, oral appliances, other therapeutic devices), Diagnostic devices (PSG Devices, home sleep testing devices, oximeters, actigraphy systems, sleep screening devices)], by end user [hospitals, home care settings, sleep clinics, ambulatory care centers, primary centers, and other end users], by age group [pediatric, below 40 years, 40-60 years, and above 60 years], by gender [male patients and female patients], and by region [North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa]. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the sleep apnea devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the sleep apnea devices market. This report covers a competitive analysis of upcoming startups in the sleep apnea devices market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall sleep apnea devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report provides insights on the following pointers:

- Analysis of key drivers (large pool of undiagnosed obstructive sleep apnea patients, favorable reimbursement and financial aid for sleep apnea devices and therapies, growing awareness about effects of untreated sleep apnea among patients, rising use of oral appliances among patients with mild-to-moderate sleep apnea, increased investments and funding to develop advanced sleep apnea products), restraints (high cost of CPAP devices and minimal insurance access in emerging economies, complex referral pathways, long waiting periods, and delayed diagnosis, and use of alternative therapies and medications for sleep apnea), opportunities (rising demand for cost-effective home sleep apnea tests, increasing focus on telemedicine, mHealth, and artificial intelligence, high growth opportunities for sleep apnea manufacturers in emerging economies) and challenges (poor patient compliance with CPAP therapy) influencing the growth of the sleep apnea devices market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the sleep apnea devices market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the sleep apnea devices market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the sleep apnea devices market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as ResMed (US), Koninklijke Philips N.V. (Netherlands), and Fisher & Paykel Healthcare Limited (New Zealand).

Table of Contents:

1	INTRODUCTION	45
1.1	STUDY OBJECTIVES	45
1.2	MARKET DEFINITION	45
1.3	STUDY SCOPE	46
1.3.1	MARKET SEGMENTATION & REGIONAL SCOPE	46
1.3.2	INCLUSIONS & EXCLUSIONS	47
1.3.3	YEARS CONSIDERED	47
1.3.4	CURRENCY CONSIDERED	48
1.4	STAKEHOLDERS	48
1.5	SUMMARY OF CHANGES	48
2	RESEARCH METHODOLOGY	50
2.1	RESEARCH DATA	50
2.1.1	RESEARCH DESIGN	50
2.1.2	SECONDARY DATA	51
2.1.2.1	List of key secondary sources	51
2.1.2.2	Key data from secondary sources	52
2.1.2.3	Objectives of secondary research	52
2.1.3	PRIMARY DATA	53
2.1.3.1	List of key primaries	53
2.1.3.2	Objectives of primary research	53
2.1.3.3	Key industry insights	54
2.1.3.4	Key data from primary sources	54
2.1.3.5	Breakdown of primary interviews	55
2.2	MARKET SIZE ESTIMATION	56
2.2.1	BOTTOM-UP APPROACH	56
2.2.1.1	Company revenue estimation approach	57
2.2.1.2	Company presentations and primary interviews	57
2.2.1.3	Patient-based approach for sleep apnea oral appliances market sizing	57

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.2.1.4	Disease burden approach for PAP devices market sizing	59
2.2.1.5	Growth forecast	59
2.2.1.6	CAGR projections	59
2.2.2	TOP-DOWN APPROACH	60
2.3	DATA TRIANGULATION	61
2.4	MARKET SHARE ANALYSIS	62
2.5	STUDY ASSUMPTIONS	62
2.5.1	MARKET ASSUMPTIONS	62
2.5.2	GROWTH RATE ASSUMPTIONS	62
2.6	RESEARCH LIMITATIONS	63
2.7	RISK ANALYSIS	63
3	EXECUTIVE SUMMARY	64
4	PREMIUM INSIGHTS	68
4.1	SLEEP APNEA DEVICES MARKET OVERVIEW	68
4.2	SLEEP APNEA DEVICES MARKET, BY PRODUCT	69
4.3	NORTH AMERICA: SLEEP APNEA DEVICES MARKET, BY PRODUCT AND COUNTRY	69
4.4	SLEEP APNEA DEVICES MARKET: REGIONAL MARKET SHARE	70
5	MARKET OVERVIEW	71
5.1	INTRODUCTION	71
5.2	MARKET DYNAMICS	71
5.2.1	DRIVERS	72
5.2.1.1	Large pool of undiagnosed obstructive sleep apnea (OSA) patients	72
5.2.1.2	Favorable reimbursement and financial aid for sleep apnea devices and therapies	73
5.2.1.3	Growing awareness about effects of untreated sleep apnea among patients	75
5.2.1.4	Rising use of oral appliances among patients with mild-to-moderate sleep apnea	76
5.2.1.5	Increased investments and funding to develop advanced sleep apnea products	77
5.2.2	RESTRAINTS	77
5.2.2.1	High cost of CPAP devices and minimal insurance access in emerging economies	77
5.2.2.2	Complex referral pathways, long waiting periods, and delayed diagnosis	78
5.2.2.3	Use of alternative therapies and medications for sleep apnea	78
5.2.3	OPPORTUNITIES	79
5.2.3.1	Rising demand for cost-effective home sleep apnea tests	79
5.2.3.2	Increasing focus on telemedicine, mHealth, and artificial intelligence	80
5.2.3.3	High growth opportunities for sleep apnea manufacturers in emerging economies	81
5.2.4	CHALLENGES	82
5.2.4.1	Poor patient compliance with CPAP therapy	82
5.3	INDUSTRY TRENDS	82
5.3.1	RISING ADOPTION OF ADVANCED SLEEP APNEA DIAGNOSTIC AND THERAPEUTIC TECHNOLOGIES	82
5.4	PRICING ANALYSIS	83
5.4.1	AVERAGE SELLING PRICE TREND OF SLEEP APNEA DEVICES, BY REGION, 2023-2025	83
5.4.2	AVERAGE SELLING PRICE TREND OF SLEEP APNEA DEVICES, BY PRODUCT TYPE, 2023-2025	84
5.4.3	AVERAGE SELLING PRICE TREND OF SLEEP APNEA ORAL APPLIANCES, BY KEY PLAYER, 2023-2025	85
5.5	VALUE CHAIN ANALYSIS	86
5.6	SUPPLY CHAIN ANALYSIS	87
5.7	UNMET NEEDS/END-USER EXPECTATIONS	88

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8	PORTER'S FIVE FORCES ANALYSIS	88
5.8.1	THREAT OF NEW ENTRANTS	89
5.8.2	THREAT OF SUBSTITUTES	90
5.8.3	BARGAINING POWER OF SUPPLIERS	90
5.8.4	BARGAINING POWER OF BUYERS	90
5.8.5	INTENSITY OF COMPETITIVE RIVALRY	91
5.9	KEY STAKEHOLDERS & BUYING CRITERIA	91
5.9.1	KEY STAKEHOLDERS IN BUYING PROCESS	91
5.9.2	KEY BUYING CRITERIA	92
5.10	ECOSYSTEM ANALYSIS	93
5.10.1	ROLE IN ECOSYSTEM	93
5.11	REGULATORY ANALYSIS	94
5.11.1	REGULATORY FRAMEWORK	94
5.11.1.1	North America	94
5.11.1.1.1	US	94
5.11.1.1.1.1	Reimbursement scenario in US	95
5.11.1.1.2	Canada	96
5.11.1.2	Europe	96
5.11.1.3	Asia Pacific	97
5.11.1.3.1	Japan	97
5.11.1.3.2	China	97
5.11.1.3.3	India	98
5.11.1.3.4	Australia	99
5.11.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	99
5.12	PATENT ANALYSIS	102
5.12.1	INSIGHTS ON PATENT PUBLICATION TRENDS (TOP APPLICANTS/ JURISDICTION)	103
5.13	ADJACENT MARKET ANALYSIS	103
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	104
5.15	KEY CONFERENCES & EVENTS, 2025?2026	105
5.16	TECHNOLOGY ANALYSIS	106
5.16.1	KEY TECHNOLOGIES	106
5.16.1.1	PAP devices	106
5.16.2	ADJACENT TECHNOLOGIES	107
5.16.2.1	Oral appliances	107
5.16.3	COMPLEMENTARY TECHNOLOGIES	107
5.16.3.1	Daytime-Nighttime appliances	107
5.17	TRADE ANALYSIS	108
5.17.1	IMPORT DATA FOR HS CODE 901849, 2020-2024	108
5.17.2	EXPORT DATA FOR HS CODE 901849, 2020-2024	108
5.18	INVESTMENT & FUNDING SCENARIO	109
5.19	IMPACT OF AI/GEN AI ON SLEEP APNEA DEVICES MARKET	109
5.19.1	MARKET POTENTIAL FOR SLEEP APNEA ORAL APPLIANCES	110
5.19.2	FUTURE OF GENERATIVE AI IN SLEEP APNEA DEVICES MARKET	111
5.20	IMPACT OF 2025 US TARIFF ON SLEEP APNEA DEVICES MARKET	112
5.20.1	INTRODUCTION	112
5.20.2	KEY TARIFF RATES	112
5.20.3	PRICE IMPACT ANALYSIS	113

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.20.4 IMPACT ON COUNTRY/REGION 113
 - 5.20.4.1 North America 113
 - 5.20.4.1.1 US 113
 - 5.20.4.2 Europe 114
 - 5.20.4.2.1 Germany 114
 - 5.20.4.2.2 UK and France 114
 - 5.20.4.3 Asia Pacific 114
 - 5.20.4.3.1 China 114
 - 5.20.4.3.2 Japan 114
 - 5.20.4.3.3 India 114
- 5.20.5 IMPACT ON END-USE INDUSTRIES 115
 - 5.20.5.1 Hospitals 115
 - 5.20.5.2 Sleep clinics 115
 - 5.20.5.3 Ambulatory surgery centers 115
 - 5.20.5.4 Primary centres 115
 - 5.20.5.5 Home care centers 115
 - 5.20.5.6 Urgent care centers 115
- 6 SLEEP APNEA DEVICES MARKET, BY PRODUCT 116
 - 6.1 INTRODUCTION 117
 - 6.2 THERAPEUTIC DEVICES 117
 - 6.2.1 PAP DEVICES 120
 - 6.2.1.1 CPAP devices 123
 - 6.2.1.1.1 Technological advancements and better reimbursement facilities to boost segment growth 123
 - 6.2.1.2 APAP devices 127
 - 6.2.1.2.1 Better customization facility to augment market growth 127
 - 6.2.1.3 BPAP devices 130
 - 6.2.1.3.1 Increased product recalls and more complex operations to lower adoption 130
 - 6.2.2 FACIAL INTERFACES 134
 - 6.2.2.1 Masks 137
 - 6.2.2.1.1 Full-face masks 142
 - 6.2.2.1.1.1 Full-face masks to be most effective for mouth breathers 142
 - 6.2.2.1.2 Nasal pillow masks 146
 - 6.2.2.1.2.1 Greater patient compliance to support segment growth 146
 - 6.2.2.1.3 Nasal masks 149
 - 6.2.2.1.3.1 Ease of use and reduced claustrophobic nature to aid adoption 149
 - 6.2.2.2 Cushions 152
 - 6.2.2.2.1 Better insurance coverage to propel segment growth 152
 - 6.2.3 ACCESSORIES 155
 - 6.2.3.1 Humidifier accessories 159
 - 6.2.3.1.1 Humidifiers to open airways, decrease congestion, and encourage clearer breathing 159
 - 6.2.3.2 Power accessories 163
 - 6.2.3.2.1 Power accessories to manage uninterrupted sleep apnea therapy without power supply 163
 - 6.2.3.3 Transportation accessories 166
 - 6.2.3.3.1 Rising need to carry sleep apnea devices while traveling to spur segment growth 166
 - 6.2.3.4 Communication accessories 169
 - 6.2.3.4.1 Need for easy teleconsultations for remote patients to fuel segment growth 169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.2.3.5	Chin restraints	173
6.2.3.5.1	Growing need for obstructive sleep apnea management with therapeutic devices to drive segment	173
6.2.3.6	Other accessories	175
6.2.4	ORAL APPLIANCES	178
6.2.4.1	Mandibular advancement devices	182
6.2.4.1.1	Low-cost devices with maximum anterior tongue space to drive segment	182
6.2.4.2	Tongue-retaining devices	186
6.2.4.2.1	Need for more affordable and comfortable treatment options to support segment growth	186
6.2.4.3	Daytime-Nighttime appliances	189
6.2.4.3.1	Increased focus on comfortable, non-surgical, and low-risk treatments to drive segment	189
6.2.5	OTHER THERAPEUTIC DEVICES	190
6.3	DIAGNOSTIC DEVICES	194
6.3.1	PSG DEVICES	197
6.3.1.1	Ambulatory PSG devices	201
6.3.1.1.1	Need for cost-effective and technologically advanced ambulatory devices to propel segment growth	201
	?	
6.3.1.2	Clinical PSG devices	204
6.3.1.2.1	Labor-intensive and expensive procedures to limit segment	204
6.3.2	HOME SLEEP TESTING DEVICES	207
6.3.2.1	Increased need for cost-effective and comfortable home sleep testing devices to augment segment growth	207
6.3.3	OXIMETERS	210
6.3.3.1	Fingertip oximeters	214
6.3.3.1.1	Lack of precise reading due to injury or slow blood flow to limit segment growth	214
6.3.3.2	Handheld oximeters	218
6.3.3.2.1	Easy customizations and ease of distant reading to spur segment growth	218
6.3.3.3	Wrist-worn oximeters	221
6.3.3.3.1	Small size and easy portability for overnight monitoring to propel segment growth	221
6.3.3.4	Tabletop oximeters	225
6.3.3.4.1	Higher cost and fewer applications for personal use to decrease market share	225
6.3.4	ACTIGRAPHY SYSTEMS	228
6.3.4.1	Increased research on sleep and wake patterns to drive market	228
6.3.5	SLEEP SCREENING DEVICES	232
6.3.5.1	Increasing preference for home-based sleep apnea testing to propel market growth	232
7	SLEEP APNEA DEVICES MARKET, BY AGE GROUP	236
7.1	INTRODUCTION	237
7.2	PEDIATRIC	237
7.2.1	PREVALENCE OF OBESITY, CRANIOFACIAL ABNORMALITIES, AND NEUROMUSCULAR DISORDERS TO PROPEL MARKET GROWTH	237
7.3	BELOW 40 YEARS	241
7.3.1	LOWER PREVALENCE OF SLEEP APNEA IN YOUNGER AGE GROUPS TO LIMIT MARKET GROWTH	241
7.4	40-60 YEARS	244
7.4.1	UNDERDIAGNOSIS AND UNHEALTHY LIFESTYLE TO AID MARKET GROWTH	244
7.5	ABOVE 60 YEARS	247
7.5.1	HIGH OCCURRENCE OF CHRONIC MEDICAL CONDITIONS AND SLEEP-RELATED DISORDERS TO DRIVE MARKET	247
8	SLEEP APNEA DEVICES MARKET, BY GENDER	251
8.1	INTRODUCTION	252
8.2	MALE PATIENTS	253

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.1 HIGHER PREVALENCE OF SLEEP-RELATED BREATHING DISORDERS TO BOOST MARKET GROWTH 253
- ?
- 8.3 FEMALE PATIENTS 255
- 8.3.1 IMPROVED RECOGNITION AND DIAGNOSIS OF OBSTRUCTIVE SLEEP APNEA TO AID MARKET GROWTH 255
- 9 SLEEP APNEA DEVICES MARKET, BY END USER 259
- 9.1 INTRODUCTION 260
- 9.2 HOSPITALS 260
- 9.2.1 INCREASED POPULARITY PRIVATE HOSPITALS WITH ADVANCED INFRASTRUCTURE TO AUGMENT MARKET GROWTH 260
- 9.3 HOME CARE SETTINGS 264
- 9.3.1 INCREASING PATIENT PREFERENCE FOR HOME-BASED SLEEP TESTS TO FUEL MARKET GROWTH 264
- 9.4 SLEEP CLINICS 268
- 9.4.1 INCREASING NEED FOR ADVANCED DIAGNOSTIC DEVICES AND SLEEP SPECIALISTS TO SUPPORT MARKET GROWTH 268
- 9.5 AMBULATORY CARE CENTERS 272
- 9.5.1 RISING ADOPTION OF PORTABLE DIAGNOSTIC DEVICES TO IMPROVE DIAGNOSIS AND TREATMENT IN OUTPATIENT SETTINGS 272
- 9.6 PRIMARY CENTERS 276
- 9.6.1 PRIMARY CENTERS TO CONDUCT FOLLOW-UP CARE AND COORDINATE PATIENTS WITH SLEEP SPECIALISTS 276
- 9.7 OTHER END USERS 279
- 10 SLEEP APNEA DEVICES MARKET, BY REGION 283
- 10.1 INTRODUCTION 284
- 10.2 NORTH AMERICA 284
- 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 284
- 10.2.2 US 292
- 10.2.2.1 US to dominate North American sleep apnea devices market during forecast period 292
- 10.2.3 CANADA 298
- 10.2.3.1 Increasing number of research grants and health programs to propel market growth 298
- 10.3 EUROPE 305
- 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 305
- 10.3.2 GERMANY 311
- 10.3.2.1 High prevalence of obstructive sleep apnea and increased geriatric population to fuel market growth 311
- 10.3.3 UK 317
- 10.3.3.1 Rising awareness among patients about sleep apnea to support market growth 317
- 10.3.4 FRANCE 323
- 10.3.4.1 Rising geriatric population and obesity rates to favor market growth 323
- ?
- 10.3.5 ITALY 328
- 10.3.5.1 Favorable initiatives by dental associations and increased awareness about obstructive sleep apnea to drive market 328
- 10.3.6 SPAIN 333
- 10.3.6.1 Social awareness initiatives by regional organizations regarding obstructive sleep apnea to aid market growth 333
- 10.3.7 REST OF EUROPE 338
- 10.4 ASIA PACIFIC 345
- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 345
- 10.4.2 CHINA 352
- 10.4.2.1 Growing prevalence of obesity and diabetes in adults to propel market growth 352
- 10.4.3 JAPAN 357
- 10.4.3.1 Favorable reimbursement scenario and high demand for cloud-connected sleep apnea therapeutic devices to aid market growth 357

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.4.4	AUSTRALIA	362
10.4.4.1	Increasing number of sleep clinics to augment market growth	362
10.4.5	REST OF ASIA PACIFIC	367
10.5	LATIN AMERICA	374
10.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	374
10.5.2	BRAZIL	381
10.5.2.1	Favorable reimbursement policies and increased awareness about sleeping disorders to drive market	381
10.5.3	MEXICO	386
10.5.3.1	Poor healthcare infrastructure and lack of public health initiatives to limit market growth	386
10.5.4	REST OF LATIN AMERICA	391
10.6	MIDDLE EAST & AFRICA	398
10.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	398
10.6.2	GCC COUNTRIES	406
10.6.2.1	Kingdom of Saudi Arabia	412
10.6.2.1.1	High obesity rates among women to propel market growth	412
10.6.2.2	UAE	418
10.6.2.2.1	Greater focus on early diagnosis and healthcare infrastructural advancements to drive market	418
10.6.2.3	Rest of GCC countries	424
10.6.3	REST OF MIDDLE EAST & AFRICA	431
11	COMPETITIVE LANDSCAPE	438
11.1	INTRODUCTION	438
11.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	438
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SLEEP APNEA DEVICES MARKET	438
	?	
11.3	REVENUE ANALYSIS, 2020-2024	440
11.4	MARKET SHARE ANALYSIS, 2024	441
11.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	442
11.5.1	STARS	442
11.5.2	EMERGING LEADERS	443
11.5.3	PERVASIVE PLAYERS	443
11.5.4	PARTICIPANTS	443
11.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	444
11.5.5.1	Company footprint	444
11.5.5.2	Region footprint	444
11.5.5.3	Product footprint	445
11.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	446
11.6.1	PROGRESSIVE COMPANIES	446
11.6.2	RESPONSIVE COMPANIES	446
11.6.3	DYNAMIC COMPANIES	446
11.6.4	STARTING BLOCKS	446
11.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	447
11.6.5.1	Detailed list of key startups/SMEs	447
11.6.5.2	Competitive benchmarking of key startups/SMEs	448
11.7	COMPANY VALUATION & FINANCIAL METRICS	449
11.7.1	FINANCIAL METRICS	449
11.7.2	COMPANY VALUATION	449
11.8	BRAND/PRODUCT COMPARISON	450

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.9	COMPETITIVE SCENARIO	450
11.9.1	PRODUCT LAUNCHES & APPROVALS	450
11.9.2	DEALS	451
11.9.3	EXPANSIONS	452
11.9.4	OTHER DEVELOPMENTS	452
12	COMPANY PROFILES	453
12.1	KEY PLAYERS	453
12.1.1	RESMED	453
12.1.1.1	Business overview	453
12.1.1.2	Products offered	454
12.1.1.3	Recent developments	457
12.1.1.3.1	Product launches	457
12.1.1.3.2	Deals	457
12.1.1.3.3	Expansions	458
12.1.1.4	MnM view	458
12.1.1.4.1	Key strengths	458
12.1.1.4.2	Strategic choices	458
12.1.1.4.3	Weaknesses & competitive threats	458
12.1.2	KONINKLIJKE PHILIPS N.V.	459
12.1.2.1	Business overview	459
12.1.2.2	Products offered	460
12.1.2.3	MnM view	462
12.1.2.3.1	Key strengths	462
12.1.2.3.2	Strategic choices	462
12.1.2.3.3	Weaknesses & competitive threats	463
12.1.3	FISHER & PAYKEL HEALTHCARE LIMITED	464
12.1.3.1	Business overview	464
12.1.3.2	Products offered	465
12.1.3.3	Recent developments	467
12.1.3.3.1	Product launches	467
12.1.3.4	MnM view	468
12.1.3.4.1	Key strengths	468
12.1.3.4.2	Strategic choices	468
12.1.3.4.3	Weaknesses & competitive threats	468
12.1.4	INSPIRE MEDICAL SYSTEMS, INC.	469
12.1.4.1	Business overview	469
12.1.4.2	Products offered	470
12.1.4.3	MnM view	470
12.1.4.3.1	Key strengths	470
12.1.4.3.2	Strategic choices	470
12.1.4.3.3	Weaknesses & competitive threats	470
12.1.5	SOMNOMED	471
12.1.5.1	Business overview	471
12.1.5.2	Products offered	472
12.1.5.3	MnM view	472
12.1.5.3.1	Key strengths	472
12.1.5.3.2	Strategic choices	472

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.5.3.3 Weaknesses & competitive threats 472
- 12.1.6 OPENAIRWAY 473
 - 12.1.6.1 Business overview 473
 - 12.1.6.2 Products offered 473
- 12.1.7 COMPUMEDICS LIMITED 474
 - 12.1.7.1 Business overview 474
 - 12.1.7.2 Products offered 475
 - 12.1.7.3 Recent developments 476
 - 12.1.7.3.1 Product approvals 476
- 12.1.8 LOWENSTEIN MEDICAL SE & CO. KG 477
 - 12.1.8.1 Business overview 477
 - 12.1.8.2 Products offered 477
- ?
- 12.1.9 DRIVE DEVILBISS INTERNATIONAL 479
 - 12.1.9.1 Business overview 479
 - 12.1.9.2 Products offered 479
- 12.1.10 BMC 480
 - 12.1.10.1 Business overview 480
 - 12.1.10.2 Products offered 480
- 12.1.11 BRAEBON MEDICAL CORPORATION 482
 - 12.1.11.1 Business overview 482
 - 12.1.11.2 Products offered 482
- 12.1.12 DYNAFLEX 483
 - 12.1.12.1 Business overview 483
 - 12.1.12.2 Products offered 483
 - 12.1.12.3 Recent developments 483
 - 12.1.12.3.1 Deals 483
- 12.1.13 PANTHERA DENTAL 484
 - 12.1.13.1 Business overview 484
 - 12.1.13.2 Products offered 484
 - 12.1.13.3 Recent developments 484
 - 12.1.13.3.1 Deals 484
 - 12.1.13.3.2 Other developments 485
- 12.1.14 MYERSON LLC 486
 - 12.1.14.1 Business overview 486
 - 12.1.14.2 Products offered 486
- 12.1.15 PROSOMNUS SLEEP TECHNOLOGIES 487
 - 12.1.15.1 Business overview 487
 - 12.1.15.2 Products offered 488
 - 12.1.15.3 Recent developments 488
 - 12.1.15.3.1 Deals 488
- 12.2 OTHER PLAYERS 489
 - 12.2.1 NIDEK MEDICAL INDIA 489
 - 12.2.2 TOMED GMBH 489
 - 12.2.3 LIVANOVA PLC 490
 - 12.2.4 INVACARE HOLDINGS CORPORATION 490
 - 12.2.5 MPOWRX HEALTH & WELLNESS PRODUCTS INC. 491

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.2.6 □NIHON KOHDEN CORPORATION □492

12.2.7 □SICAT GMBH & CO. KG □493

12.2.8 □VIVOS THERAPEUTICS, INC. □494

12.2.9 □AIRWAY MANAGEMENT □495

12.2.10 □APNEA SCIENCES □496

?

13 □APPENDIX □497

13.1 □DISCUSSION GUIDE □497

13.2 □KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL □501

13.3 □CUSTOMIZATION OPTIONS □503

13.4 □RELATED REPORTS □503

13.5 □AUTHOR DETAILS □504

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Sleep Apnea Devices Market by Product (Therapeutic (PAP (CPAP, APAP, BPAP), Oral Appliances, Masks), Diagnostic (PSG, Home Sleep Testing, Oximeter)), Age, Gender, End User (Sleep Clinics, Hospitals, Home Care Settings) - Global Forecast to 2032

Market Report | 2025-07-18 | 505 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-16

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com